These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6390997)

  • 1. [Venous tonus-modifying effect, pharmacokinetics and undesired effects of dihydroergotamine].
    Barthel W
    Z Gesamte Inn Med; 1984 Sep; 39(17):417-28. PubMed ID: 6390997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs.
    Müller-Schweinitzer E; Rosenthaler J
    J Cardiovasc Pharmacol; 1987 Jun; 9(6):686-93. PubMed ID: 2442535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.
    Barthel W; Glusa E; Koth W
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):63-9. PubMed ID: 2881898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental pharmacological studies of the venous tonus-modifying effect of dihydroergotamine].
    Glusa E
    Z Gesamte Inn Med; 1984 Sep; 39(17):414-7. PubMed ID: 6095548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Complications following preventive treatment of thromboembolism with Dihydergot-heparin].
    Andersen KH; Jeppesen IS
    Ugeskr Laeger; 1989 Aug; 151(33):2072-5. PubMed ID: 2672498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics and pharmacokinetics of dihydroergotamine (DHE) in conscious beagle dogs.
    Müller-Schweinitzer E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):162-5. PubMed ID: 2459013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of dihydroergotamine (DHE) on blood volume and circulation in the calf in peridural anesthesia in the human].
    Stühmeier KD; Stanton-Hicks M; Arndt JO
    Reg Anaesth; 1987 Oct; 10(4):109-13. PubMed ID: 3685475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing.
    de Marées H; Welzel D; de Marées A; Klotz U; Tiedjen KU; Knaup G
    Eur J Clin Pharmacol; 1986; 30(6):685-9. PubMed ID: 3533566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is known about the action of dihydroergotamine on the vasculature in man?
    Müller-Schweinitzer E
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):677-82. PubMed ID: 6396240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of therapy with microcirculatory and phlebotropically active drugs in patients with congenital and acquired venous insufficiency.
    Wenzel E; Birkel L; Scheffler P; Waldhausen P; Jung F
    Int Angiol; 1989; 8(1):41-6. PubMed ID: 2549130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of dihydroergotamine in man.
    Little PJ; Jennings GL; Skews H; Bobik A
    Br J Clin Pharmacol; 1982 Jun; 13(6):785-90. PubMed ID: 7093108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative plethysmographic study of the venoconstrictor effect of dihydroergotamine and dihydroergotoxine on the deep veins of the calf in healthy subjects and patients suffering from varicosis.
    Barthel W; Grossmann K
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):458-64. PubMed ID: 7141753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulatory effects of dihydroergotamine in patients with disturbed sympathetic vasomotor control with special reference to postural hypotension.
    Bevegård S; Castenfors J; Lindblad LE
    Cardiology; 1976; 61 suppl 1():322-32. PubMed ID: 975147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of the venous reservoir in maintaining arterial pressure during hemodialysis. Effect of dihydroergotamine].
    Aubert P; Chaignon M; Leguy P; Delbart H; Lucsko M; Guedon J
    Nephrologie; 1982; 3(4):171-5. PubMed ID: 7155274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ergotism--a serious complication in the chemical prevention of thromboembolism with heparin-DHE].
    van den Berg E; Walterbusch G; Gotzen L; Rumpf KD; Otten B; Fröhlich H
    Vasa; 1983; 12(1):64-7. PubMed ID: 6837130
    [No Abstract]   [Full Text] [Related]  

  • 16. [Duplex sonography of the popliteal vein using physiologic conditions and following intravenous administration of dihydroergotamine].
    Eichlisberger R; Huber P; Jäger K
    Vasa; 1989; 18(3):221-6. PubMed ID: 2678803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and therapy of ergotism following the use of heparin-DHE in thrombosis prevention].
    Wiesmann W; Peters PE; Irskens U; Schwering H
    Rofo; 1987 Oct; 147(4):446-9. PubMed ID: 2825270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
    Lipton RB
    Headache; 1997; 37 Suppl 1():S33-41. PubMed ID: 9009472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension.
    Bobik A; Jennings G; Skews H; Esler M; McLean A
    Clin Pharmacol Ther; 1981 Nov; 30(5):673-9. PubMed ID: 6794970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection.
    Kanto J; Allonen H; Koski K; Koulu M; Lammintausta R; Mäntylä R; Kleimola T; Siirtola T
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):127-30. PubMed ID: 7228454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.